Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Biotech
Sanofi pens $395M China pact for Arrowhead metabolic med
Sanofi is handing over $130 million upfront for the China rights to Arrowhead’s rare metabolic disease drug currently being considered for approval.
James Waldron
Aug 1, 2025 7:21am
Arrowhead reassures investors about pact with troubled Sarepta
Jul 23, 2025 10:13am
Biogen blueprints $1B CNS deal with RNAi biotech
May 27, 2025 10:55am
Arrowhead shares ‘select’ data for RNAi asset in kidney trial
Mar 10, 2025 11:55am
Alnylam abandons clinical-stage Type 2 diabetes asset
Oct 31, 2024 10:27am
City Tx breaks ground with $135M, blueprints from Maraganore
Oct 8, 2024 10:38am
